copper Cu 64-DOTA-rituximab

{
  "id": "MLC-T-ONC-012761",
  "term": "copper Cu 64-DOTA-rituximab",
  "field": "Oncology and biomedicine",
  "definition": "A radioimmunoconjugate containing rituximab, a recombinant chimeric murine/human antibody directed against the human CD20 antigen, conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the radioisotope copper Cu 64 with potential diagnostic properties upon positron emission tomography (PET) imaging. The monoclonal antibody moiety of copper Cu 64-DOTA-Rituximab specifically binds to cell surface antigen CD20. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of CD20-expressing tumor cells. CD20 is a non-glycosylated phosphoprotein that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.",
  "synonyms": [
    "64Cu-DOTA-rituximab"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/copper-cu-64-dota-rituximab/"
}